Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aura Biosciences, Inc. (AURA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aura Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1501796.
Total stock buying since 2021: $51,818,365.
Total stock sales since 2021: $2,257,045.
Total stock option exercises since 2021: $283,414.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 20,000 | $98,000 | 111,667 | $837,979 | 12,899 | $57,839 |
| 2024 | 0 | $0 | 101,543 | $1,062,960 | 55,597 | $204,477 |
| 2023 | 1,781,667 | $15,663,968 | 24,320 | $225,237 | 7,700 | $21,098 |
| 2022 | 84,000 | $1,126,397 | 10,508 | $130,869 | 0 | $0 |
| 2021 | 2,495,000 | $34,930,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 7,722 | $51,737 | 12,899 | $57,839 |
| 2025-05 | 20,000 | $98,000 | 0 | $0 | 0 | $0 |
| 2025-04 | 0 | $0 | 8,059 | $44,243 | 0 | $0 |
| 2025-02 | 0 | $0 | 78,930 | $611,946 | 0 | $0 |
| 2025-01 | 0 | $0 | 16,956 | $130,053 | 0 | $0 |
| 2024-11 | 0 | $0 | 11,822 | $110,665 | 0 | $0 |
| 2024-10 | 0 | $0 | 67,259 | $780,628 | 50,123 | $172,947 |
| 2024-09 | 0 | $0 | 0 | $0 | 5,474 | $31,530 |
| 2024-01 | 0 | $0 | 22,462 | $171,667 | 0 | $0 |
| 2023-11 | 1,759,601 | $15,474,987 | 11,349 | $136,664 | 7,700 | $21,098 |
| 2023-10 | 20,066 | $168,171 | 12,971 | $88,573 | 0 | $0 |
| 2023-01 | 2,000 | $20,810 | 0 | $0 | 0 | $0 |
| 2022-12 | 34,000 | $410,097 | 0 | $0 | 0 | $0 |
| 2022-10 | 0 | $0 | 10,508 | $130,869 | 0 | $0 |
| 2022-06 | 50,000 | $716,300 | 0 | $0 | 0 | $0 |
| 2021-11 | 2,495,000 | $34,930,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | Elazzouzi Amy (Senior Vice President, Finance) | Sale | 7,722 | 6.70 | 51,737 |
| 2025-08-18 | Elazzouzi Amy (Senior Vice President, Finance) | Option Ex | 12,899 | 4.48 | 57,839 |
| 2025-05-16 | Johnson David Michael | Buy | 20,000 | 4.90 | 98,000 |
| 2025-04-16 | Elazzouzi Amy (Senior Vice President, Finance) | Sale | 897 | 5.49 | 4,924 |
| 2025-04-16 | Kilroy Conor (See Remarks) | Sale | 7,162 | 5.49 | 39,319 |
| 2025-02-18 | Elazzouzi Amy (Senior Vice President, Finance) | Sale | 2,808 | 7.75 | 21,762 |
| 2025-02-18 | Hopkins Janet Jill (Chief Medical Officer) | Sale | 5,068 | 7.75 | 39,276 |
| 2025-02-18 | De Los Pinos Elisabet (See Remarks) | Sale | 40,442 | 7.75 | 313,586 |
| 2025-02-18 | Plavsic Mark (Chief Technology Officer) | Sale | 4,302 | 7.75 | 33,340 |
| 2025-01-21 | Elazzouzi Amy (Vice President, Finance) | Sale | 1,001 | 7.67 | 7,679 |
| 2025-01-21 | De Los Pinos Elisabet (See Remarks) | Sale | 15,955 | 7.67 | 122,374 |
| 2024-11-18 | Hopkins Janet Jill (Chief Medical Officer) | Sale | 11,822 | 9.36 | 110,665 |
| 2024-10-29 | Elazzouzi Amy (Vice President, Finance) | Sale | 553 | 10.74 | 5,938 |
| 2024-10-29 | De Los Pinos Elisabet (See Remarks) | Sale | 9,200 | 10.74 | 98,789 |
| 2024-10-18 | De Los Pinos Elisabet (See Remarks) | Sale | 24,992 | 12.04 | 300,828 |
| 2024-10-18 | De Los Pinos Elisabet (See Remarks) | Option Ex | 24,992 | 2.74 | 68,478 |
| 2024-10-18 | Feder Julie B (Chief Financial Officer) | Sale | 25,131 | 12.03 | 302,351 |
| 2024-10-18 | Feder Julie B (Chief Financial Officer) | Option Ex | 25,131 | 4.16 | 104,469 |
| 2024-10-16 | Plavsic Mark (Chief Technology Officer) | Sale | 7,383 | 9.85 | 72,722 |
| 2024-09-27 | De Los Pinos Elisabet (See Remarks) | Option Ex | 5,474 | 5.76 | 31,530 |
| 2024-01-23 | De Los Pinos Elisabet (See Remarks) | Sale | 15,853 | 7.64 | 121,148 |
| 2024-01-23 | Feder Julie B (Chief Financial Officer) | Sale | 6,609 | 7.64 | 50,519 |
| 2023-11-09 | Goel David E. | Buy | 1,560,000 | 9.00 | 14,040,000 |
| 2023-11-08 | Johnson David Michael | Buy | 29,601 | 7.30 | 216,087 |
| 2023-11-07 | Johnson David Michael | Buy | 170,000 | 7.17 | 1,218,900 |
| 2023-11-06 | De Los Pinos Elisabet (See Remarks) | Sale | 7,449 | 12.03 | 89,611 |
| 2023-11-06 | De Los Pinos Elisabet (See Remarks) | Option Ex | 3,800 | 2.74 | 10,412 |
| 2023-11-06 | Feder Julie B (Chief Financial Officer) | Sale | 3,900 | 12.06 | 47,053 |
| 2023-11-06 | Feder Julie B (Chief Financial Officer) | Option Ex | 3,900 | 2.74 | 10,686 |
| 2023-10-30 | De Los Pinos Elisabet (See Remarks) | Sale | 9,586 | 6.83 | 65,481 |
| 2023-10-30 | Feder Julie B (Chief Financial Officer) | Sale | 3,385 | 6.82 | 23,092 |
| 2023-10-04 | Johnson David Michael | Buy | 6,566 | 8.61 | 56,513 |
| 2023-10-03 | Johnson David Michael | Buy | 13,500 | 8.27 | 111,658 |
| 2023-01-06 | Johnson David Michael (Director) | Buy | 1,604 | 10.51 | 16,850 |
| 2023-01-05 | Johnson David Michael (Director) | Buy | 396 | 10.00 | 3,960 |
| 2022-12-28 | Johnson David Michael (Director) | Buy | 4,000 | 9.75 | 39,000 |
| 2022-12-01 | Johnson David Michael (Director) | Buy | 20,000 | 12.37 | 247,398 |
| 2022-10-31 | Rich Cadmus (See Remarks) | Sale | 1,672 | 12.45 | 20,813 |
| 2022-10-31 | De Rosch Mark (Chief Operating Officer) | Sale | 1,115 | 12.46 | 13,889 |
| 2022-10-31 | De Los Pinos Elisabet (See Remarks) | Sale | 5,706 | 12.46 | 71,079 |
| 2022-10-31 | Feder Julie B (Chief Financial Officer) | Sale | 2,015 | 12.45 | 25,088 |
| 2022-06-13 | Johnson David Michael (Director) | Buy | 34,000 | 13.99 | 475,660 |
| 2022-06-10 | Johnson David Michael (Director) | Buy | 16,000 | 15.04 | 240,640 |
| 2021-11-02 | Medicxi Growth I Gp Ltd (10% Owner) | Buy | 710,000 | 14.00 | 9,940,000 |
| 2021-11-02 | Goel David E. | Buy | 1,785,000 | 14.00 | 24,990,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of AURA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aura Biosciences, Inc. (symbol AURA, CIK number 1501796) see the Securities and Exchange Commission (SEC) website.